<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C67ECDD3-918C-4095-B59F-3E63D4016E9E"><gtr:id>C67ECDD3-918C-4095-B59F-3E63D4016E9E</gtr:id><gtr:firstName>Pietro</gtr:firstName><gtr:surname>Fratta</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000287"><gtr:id>B2610F84-3F71-4ACE-BA18-210FB0628165</gtr:id><gtr:title>Characterization and molecular investigation of pathogenesis in a novel model of human familial ALS.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000287</gtr:grantReference><gtr:abstractText>Amyotrophic lateral sclerosis, (ALS, also called Motor neurone disease) causes progressive paralysis due to the degeneration of motor nerve cells in the brain and spinal cord. People lose the ability to move their limbs, eat or speak and die from breathlessness, usually within 3 years of symptom onset. There is no effective treatment for the disease. 

ALS can occur in one individual or within families when a defective gene is passed down through the generations. No clinical characteristic differentiates the familial forms from the others. SOD1 is the most frequently involved gene and the study of SOD1 defects is an opportunity for understanding ALS disease mechanisms and to identify therapeutic targets. 

The purpose of this research project is to study a new mouse model which carries the exact same genetic defect as a group of ALS patients. 

We will characterize the disease progression in the mice and so we will use the mice to analyze the disease mechanisms in the motor nerve cells in the very early stages of disease. The discovery of underlying disease mechanisms is fundamental to the identifying drug targets for clinical trials, and the mice may also be used as a disease model to test new therapies.</gtr:abstractText><gtr:technicalSummary>Background
ALS is a relentlessly progressive disease, characterized by the degeneration of motor neurons in brain and spinal cord. 10% of cases are familial (fALS) and SOD1 is the most frequent causative gene. fALS and sporadic ALS (sALS) are clinically indistinguishable and misfolded SOD1 is found in sALS patients? spinal cords, making the study of SOD1-fALS relevant also to the sporadic disease. The discovery of fALS-causing mutations in TARDBP and FUS genes, both encoding RNA processing proteins, has highlighted the role of RNA in ALS pathogenesis and, intriguingly, mutant SOD1 (mtSOD1) has been shown to influence mRNA stability.

Numerous ALS transgenic mouse models are available and all overexpress mtSOD1, generating a biological context very different from that of patients, thus affecting studies of pathobiology, early-stage disease and therapeutics. No mouse models expressing endogenous levels of mutated protein have been generated on the assumption that over-expression is necessary to generate a motor phenotype.

The Fisher laboratory has mice carrying and endogenously expressing a single point mutation causative for human fALS (SOD1-D83G). We have preliminary data showing these mice develop a motor phenotype by 9 months of age, therefore providing a powerful tool for analyzing early-stage disease and the role of mutant SOD1 in RNA stability and pathophysiology. 

Aims and Objectives
This project aims to define and characterize the progression of disease in this mouse line, compare with human pathology and then investigate early-stage motorneuron molecular changes. 

Design and Methodology
1.Define disease time-course by longitudinal analysis.
- Motor phenotype will be analysed in statistically valid cohorts by monthly assessments including SHIRPA, rotarod, gripstrength. 
- Muscle physiology and histopathology of brain, spinal cord, nerve, muscle will be assessed at 4 time-points. 
- Spinal cord and brain pathology will be compared with post-rtem material from fALS-SOD1-D83G cases.
2.Study subtle preclinical-ALS changes.
We will analyze the motorneuron transcriptome by RNA-Seq analysis at the pre-clinical and early stage of disease. Results will be validated by real-time Q-PCR. These data will allow us to:
1) identify new pathogenetic molecular players and pathways; 
2) verify pathways currently hypothesized to be involved in ALS; 
3) investigate mRNAs known to be regulated by SOD1.

Scientific and Medical Opportunities
The development of valid disease models is a crucial step for both our understanding of ALS pathogenesis and the development of therapy. 
SOD1-D83G mice avoid overexpression related artefacts and develop a slowly progressive disease, therefore offering the invaluable opportunity to study the subtle changes of the preclinical stage. Further, the availability of human post-mortem cases carrying the same mutation will allow us to compare human and mouse pathology. Studies of this type are extremely important and very rare in the current medical literature.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>259146</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Massachusetts Institute of Technology (MIT)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>RNA sequencing</gtr:description><gtr:id>7C1BCD27-6FAD-4F69-A079-0BACEF1F5476</gtr:id><gtr:impact>Outputs have been full datasets obtained on our mutant mouse lines.</gtr:impact><gtr:outcomeId>ZfnS6zzcs9H-1</gtr:outcomeId><gtr:partnerContribution>Sequencing and initial analysis of the RNA sequencing data.</gtr:partnerContribution><gtr:piContribution>Collection, isolation and processing of different Central Nervous System samples originating from our novel mutant mouse lines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Generation of novel mouse models</gtr:description><gtr:id>CC614AF6-14D5-43AD-A10D-1978742E0DE6</gtr:id><gtr:impact>This collaboration has led to numerous findings - manuscripts are in preparation.</gtr:impact><gtr:outcomeId>YRnVSe6ZzPE-1</gtr:outcomeId><gtr:partnerContribution>Generated novel mouse mutants for the study of ALS related genes Fus, Tardbp and Sod1</gtr:partnerContribution><gtr:piContribution>Studied molecular features and RNA profile of novel lines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Genetics Institute</gtr:department><gtr:description>Bioinformatics analysis</gtr:description><gtr:id>BCABA7B0-F2BD-417A-8F60-2304D6BDBA42</gtr:id><gtr:impact>This collaboration has resulted in significant progress of our understanding and capacity to interpret complex sequencing data. This has resulted in 2 publications (acceptes, but not yet in press)</gtr:impact><gtr:outcomeId>nqBtYMtsprp-1</gtr:outcomeId><gtr:partnerContribution>Bioinformatic analysis and processing of sequencing data</gtr:partnerContribution><gtr:piContribution>We provided data generation, data analysis and wet-lab validation of data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MND open day - National Hospital of Neurology and Neurosurgery</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6EA96851-BB0B-4382-BDA9-DC67334DF6D6</gtr:id><gtr:impact>50 patients and carers took part in the Open Day.

Understanding of our reasearch activities and requests to actively participate in research</gtr:impact><gtr:outcomeId>kv2tVQ5Q7sz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regular commenting on MNDA and KD Disease association blogs and newsletters</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>08EF4CFE-1463-4A25-9149-51794469547A</gtr:id><gtr:impact>Explained findings and research plans to patient audiences.</gtr:impact><gtr:outcomeId>56e0208b3da0b1.61403266</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>378214</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>04EF2152-D4E9-49EA-A297-D5BDFE8C13A4</gtr:id><gtr:outcomeId>Y1xgh5vjkHy</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Thierry Latran Foundation</gtr:fundingOrg><gtr:id>316AE4B3-172B-44FE-B9F5-DC6956E3DDD4</gtr:id><gtr:outcomeId>joeu4JkenjZ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new mouse line carrying a pathogenic ALS mutation and developing signs of motorneuron degeneration. Different from all previous published lines in that the mutation is in the endogenous mouse gene.</gtr:description><gtr:id>1EF4F031-B793-4AE2-A504-91A7E8FDC076</gtr:id><gtr:impact>This has highlighted the importance of dosage in pathogenesis of animal models, and also underlined the integarted loss and gain of function occurring in SOD1 ALS.</gtr:impact><gtr:outcomeId>KcULiS772rS</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Sod1 D83G mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>isolation of few cells from mouse tissue followed by RNA extraction, amplification and sequencing</gtr:description><gtr:id>FD77886A-0308-449D-B4C1-D16D7501C4D6</gtr:id><gtr:impact>possibility of obtaining a transcriptome from few mouse tissue cells</gtr:impact><gtr:outcomeId>iGyrQ43pEXg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>few cell transcriptomics</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BAD5B2EA-E881-43C6-8D57-2A74F21D1115</gtr:id><gtr:title>A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56deff0b0bf8a8.92724580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5188887-622F-45D5-870D-F4997A9AB5D9</gtr:id><gtr:title>C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32f0eec9d99a9f9c30f1d78b95480322"><gtr:id>32f0eec9d99a9f9c30f1d78b95480322</gtr:id><gtr:otherNames>Mizielinska S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_16189_29_24170096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29B6E51C-4B5A-4AC8-9B1E-3F0350D6BE5B</gtr:id><gtr:title>FUS is not dysregulated by the spinal bulbar muscular atrophy androgen receptor polyglutamine repeat expansion.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16189_29_23062703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9212EA5C-A09A-4589-BE44-C80174293CFE</gtr:id><gtr:title>Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56deff09e2c5d2.21853524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2FD05FC-3035-49F0-B309-B72AB8F42969</gtr:id><gtr:title>Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_16189_29_23818065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1080F93-B017-443C-AFCB-A4BAF5007303</gtr:id><gtr:title>Correlation of clinical and molecular features in spinal bulbar muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>545b8748a23ee4.06514914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53854A82-AB66-4B30-A285-BD354F314CD6</gtr:id><gtr:title>Recent advances in bulbar syndromes: genetic causes and disease mechanisms.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ffda67425e994f02c670de63593986"><gtr:id>c9ffda67425e994f02c670de63593986</gtr:id><gtr:otherNames>Manole A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>545b8749490165.32770426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80570351-C95A-44DE-8E08-D98F93EFE2CF</gtr:id><gtr:title>C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32f0eec9d99a9f9c30f1d78b95480322"><gtr:id>32f0eec9d99a9f9c30f1d78b95480322</gtr:id><gtr:otherNames>Mizielinska S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>545b8749224855.13467396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30F8ACA1-4C27-4BA8-BD28-28C6982D14E1</gtr:id><gtr:title>Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_16189_29_23434116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9D90F4-2D2D-45D0-9F11-345713A05C59</gtr:id><gtr:title>Sequencing analysis of the spinal bulbar muscular atrophy CAG expansion reveals absence of repeat interruptions.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16189_29_24041967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C259C1-EEBF-4712-AE23-8D4E8E77E39B</gtr:id><gtr:title>Is SOD1 loss of function involved in amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fd54e97f8d443160f933229c72f332"><gtr:id>03fd54e97f8d443160f933229c72f332</gtr:id><gtr:otherNames>Saccon RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16189_29_23687121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B36F57-6915-4F2F-83B2-595216C7FCB9</gtr:id><gtr:title>Investigation of next-generation sequencing technologies as a diagnostic tool for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56deff0bd240e4.29540982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD72C8FA-5294-4852-A666-1CB9D6C2FF89</gtr:id><gtr:title>SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.</gtr:title><gtr:parentPublicationTitle>Mammalian genome : official journal of the International Mammalian Genome Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0938-8990</gtr:issn><gtr:outcomeId>56deff0c2361f0.06214218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5AE267C-FB0B-48EB-868A-455A9CE724CE</gtr:id><gtr:title>A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/311b04aa4c17b316103c9775174f68e9"><gtr:id>311b04aa4c17b316103c9775174f68e9</gtr:id><gtr:otherNames>Ricketts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545b87485910e7.07955401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B3D3D4-F7B7-4315-9DA3-908DB6754851</gtr:id><gtr:title>Profilin1 E117G is a moderate risk factor for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56defe9ad50a38.70536041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6186A331-6DAE-4EE0-97E3-317B02C3DB95</gtr:id><gtr:title>Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae312a95b658688d9e502f838b047b75"><gtr:id>ae312a95b658688d9e502f838b047b75</gtr:id><gtr:otherNames>Corrochano S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>545b8749acb5a6.47712434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D611A07B-5CD5-4385-80E0-653726D757C1</gtr:id><gtr:title>Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe424690789fe3b498adf4ad55c8999b"><gtr:id>fe424690789fe3b498adf4ad55c8999b</gtr:id><gtr:otherNames>Lu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>545b8748ed42c7.85949737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63D4A161-6FF8-4B46-AD0D-6A86A1E5790A</gtr:id><gtr:title>Graphical modelling of molecular networks underlying sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5d2ace43ac20075ac8ea1ef8005d62"><gtr:id>7d5d2ace43ac20075ac8ea1ef8005d62</gtr:id><gtr:otherNames>Thorne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>pm_16189_29_23595110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1E56378-8EBD-4DBC-AFDA-41C002AA0765</gtr:id><gtr:title>C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_16189_29_23264878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E48B9F7-DE95-4EFF-8568-093654CD232D</gtr:id><gtr:title>Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18049378950e97e3da96e50d647b5c6f"><gtr:id>18049378950e97e3da96e50d647b5c6f</gtr:id><gtr:otherNames>Johnson JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>545b87487f5013.12977477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4BDB3E1-EB97-4C89-BED3-36724745D73E</gtr:id><gtr:title>Antisense makes sense for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_16189_29_23541757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D57B71BA-2B68-4270-9DD2-B1F21491433D</gtr:id><gtr:title>SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes.</gtr:title><gtr:parentPublicationTitle>The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b43d32f2b6cfef312c3c6a528071c8e6"><gtr:id>b43d32f2b6cfef312c3c6a528071c8e6</gtr:id><gtr:otherNames>Bunton-Stasyshyn RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-8584</gtr:issn><gtr:outcomeId>56deff0a42ff68.12161531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EFDAF49-AFF8-4592-BAC8-C1C8C73544A8</gtr:id><gtr:title>Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>545b8749747a40.71919649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE635A6E-3E47-4774-8EB8-86213188E38A</gtr:id><gtr:title>An unusual presentation for SOD1-ALS: isolated facial diplegia.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_16189_29_23873540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADACA2F0-DDC0-44F1-B33C-C76582944109</gtr:id><gtr:title>Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3b1f101fc39803c11f89c7209db490"><gtr:id>8b3b1f101fc39803c11f89c7209db490</gtr:id><gtr:otherNames>Cortese A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>545b874835d312.04112879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0A2A288-7F08-456D-B4B3-0C8516C26CE2</gtr:id><gtr:title>Novel CLN3 mutation causing autophagic vacuolar myopathy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3b1f101fc39803c11f89c7209db490"><gtr:id>8b3b1f101fc39803c11f89c7209db490</gtr:id><gtr:otherNames>Cortese A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>545b8748c970f1.74532430</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000287</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>